Zatsopano Zatsopano pa Matenda a Alzheimer's ndi Parkinson

Asceneuron SA lero yalengeza kufalitsidwa kwa deta yowunikiridwa ndi anzawo mu nyuzipepala ya ACS Chemical Neuroscience yokhudzana ndi ASN90, inhibitor ya O-GlcNAcase (OGA), komanso m'modzi mwa omwe adatsogolera pakukula kwachipatala pochiza matenda a neurodegenerative proteinopathies.

Neurodegenerative proteinopathies monga Alzheimer's ndi Parkinson's disease imadziwika ndi mapangidwe a intracellular mu ubongo wa aggregates osasungunuka komanso owopsa a mapuloteni, monga mapuloteni a tau ndi α-synuclein motsatana, omwe amagwirizana kwambiri ndi matenda. OGA ndiye chandamale chamankhwala chomwe chikubwera pakukulitsa kwamankhwala amitsempha yapakati popeza kuchepa kwa glycosylation kwa mapuloteni olowa mkati mwa cell kumalumikizidwa ndi vuto la neuronal. Ma OGA inhibitors amalepheretsa kuchotsedwa kwa mapuloteni a intracellular glycosylation, motero amaletsa kutsika kwa mkhalidwe wathanzi pakusinthidwa kwapambuyo kumasuliraku ndikuletsa kupanga magulu oopsa a protein.

Mu pepala lowunikiridwa posachedwa, Asceneuron ikunena za kupezeka koyambirira komanso kakulidwe ka buku laling'ono la OGA inhibitor ASN90 (lomwe poyamba limadziwika kuti ASN120290/ASN561), lomwe lamaliza kale kuyesa m'maphunziro atatu a Phase I m'maphunziro achichepere ndi okalamba athanzi. . Deta ya preclinical ikuwonetsa kuti kuwongolera pakamwa tsiku lililonse kwa ASN90 kumalepheretsa kukula kwa tau tangle pathology, komanso kuchepa kwa magwiridwe antchito amagalimoto ndi kupuma, komanso kupulumuka kwachulukidwe. Kupeza kwina kofunikira; buku la gulu ili la mamolekyu; ndikuti ASN90 idachedwetsa kufalikira kwa kuwonongeka kwa magalimoto ndikuchepetsa astrogliosis m'chitsanzo chogwiritsidwa ntchito pafupipafupi cha matenda a Parkinson.

Asceneuron pakadali pano ili ndi pulogalamu yotseguka yofufuza mankhwala atsopano (IND) ndi US Food and Drug Association (FDA) pa kafukufuku wa Phase 2/3 kuti aunike ASN90 mu progressive supranuclear palsy (PSP), chizindikiro cha ana amasiye. PSP ndi matenda osowa a m'mitsempha omwe amachititsa mavuto aakulu ndi kuyenda, kuyenda bwino, kulankhula, kumeza ndi kuona chifukwa cha kudzikundikira kwa mapuloteni a tau mu ubongo. Matendawa amakula pang'onopang'ono, ndipo anthu amakhala olumala kwambiri mkati mwa zaka zitatu kapena zisanu atayamba. Akuti anthu atatu kapena asanu ndi mmodzi mwa anthu 100,000 aliwonse adzakhala ndi PSP ndipo pakadali pano palibe mankhwala ochiza matendawa.

A Dirk Beher, Chief Executive Officer, Co-Founder wa Asceneuron komanso wolemba wamkulu wa kafukufukuyu, adati: "Ndife okondwa kufalitsa zidziwitso zolimbikitsa za ASN90 ndi njira ya OGA. Zomwe anapezazi zimapereka zifukwa zomveka bwino za chitukuko cha OGA inhibitors monga mankhwala osintha matenda mu tauopathies ndi α-synucleinopathies monga Alzheimer's, PSP, ndi Parkinson's disease. Popeza tau ndi α-synuclein pathologies nthawi zambiri amakhalapo mu matenda a neurodegenerative, OGA inhibitors amayimira apadera, omwe akufuna kukhala ndi mankhwala osiyanasiyana pazowonetsa zingapo. Tikupitiliza kupititsa patsogolo chitukuko chathu chachipatala ndi OGA inhibitor yathu yaposachedwa, ASN51, yomwe iperekedwa kwa odwala matenda a Alzheimer's m'miyezi ikubwerayi.